ClinicalTrials.gg
Active, not recruitingNCT04290793Updated Jan 7, 2026

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

A Phase 2/3 interventional study of Pyrotinib and Epirubicin in Breast Cancer, sponsored by Hebei Medical University Fourth Hospital. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Hebei Medical University Fourth Hospital · Phase 2/3, Interventional, and Treatment

How we know · 11 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
113
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies testing pyrotinib in Breast Neoplasms — 49 open to participants now, 57 under way, 13 of them phase 3. pyrotinib · Breast Neoplasms.

Planned enrollment
47th of 101
113 · median 100
Started
2020
with 12 others
Phase 2/3
2 of 101
1 open now
Primary completion
2026-12
later than 33 of 56 live
Registered
33rd of 101
by date

Among the 101 studies testing pyrotinib in Breast Neoplasms, this one is the 47th largest by planned enrollment, is one of 13 that started in 2020, is one of 2 in phase 2/3, reaches primary completion later than 33 of the 56 other live ones, and was the 33rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

49 of the 101 studies testing pyrotinib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

Where they have run

About pyrotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing pyrotinib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, open label, single-arm study to evaluate the efficacy and safety of neoadjuvant pyrotinib in HER2+ breast cancer patients

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female breast cancer patients at the age of >= 18 years and \<= 70 years who received first treatment;
  2. confirmed -positive invasive breast cancer(which is defined as the immunohistochemistry score of > 10% immunoreactive cells being 3+ or in situ hybridization results showing HER2 gene amplification),regardless of hormone receptor status (ER and PR);
  3. According to the 2019 CSCO BC guidelines: When HER-2 positive is used as the standard for preoperative therapy for breast cancer, the tumor is larger than 2 cm;
  4. The Eastern Tumor Collaborative Group () has a physical status score of ≤1;
  5. The functional level of the main organs must meet the following requirements : 1) blood routine test: (Hb) ≥ 90g/L;Neutrophils (ANC) ≥ 1.5 × 10\^9/L; count (PLT) ≥ 90 × 10\^9/L; 2) Blood biochemistry: Total (TBIL) ≤ 1.5 value (ULN); (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; Urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN; 3) Heart color ultrasound: (LVEF) ≥ 55%;
  6. Women of childbearing age, tested negative for serum pregnancy test 7 days before randomization,and willing to use appropriate methods during the trial and within 8 weeks after the last administration of the test drug;
  7. A volunteer to participate in the study; provision of written ; good compliance and willing to cooperate during the follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Known history of to pyrotinib or any of it components;
  2. Patients have previously received antitumor treatment or radiation therapy for any malignant tumor (except for cervical carcinoma in situ and basal cell carcinoma that have been cured);
  3. Patients underwent major breast cancer-free surgery within 4 weeks and have not fully recovered;
  4. Subjects that are unable to swallow tablets,intestinal obstruction or dysfunction of gastrointestinal absorption;
  5. Patients with severe heart disease or discomfort who cannot be treated;
  6. The patient suffers from mental illness or psychotropic substance abuse and cannot cooperate;
  7. Pregnant or lactating women;
  8. Less than 4 weeks from the last clinical trial;
  9. Patients participating in other clinical trials at the same time
  10. The researchers think inappropriate.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
113 participants (estimated)

Study arms

  • Active comparator
    Experimental group

    Patients will receive the test drug (Pyrotinib) combined with Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab with Pyrotinib

    Drug: Pyrotinib · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Taxanes · Biological: Trastuzumab

Interventions

  • 400mg administered as continuous oral once daily from the first day of the study

  • 90mg/m\^2 d1 iv Q2W for 4 cycles

  • 600 mg/m\^2 d1 iv Q2W for 4 cycles

  • DrugTaxoidsStudies of TaxoidsTaxoids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Albumin paclitaxel(125mg/m2 d1、8 iv Q3W for 4 Cycles)/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )

  • BiologicalTrastuzumab

    the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W

06

What researchers measure

Primary outcomes

  1. tpCR

    It is defined as the absence of residual invasive carcinoma in the resected breast cancer specimens stained with hematoxylin and eosin, and no cancer metastasis in all ipsilateral lymph node samples, after completion of neoadjuvant therapy and surgery.

    Time frame: immediately after surgery

Secondary outcomes

  1. Objective Response Rate(ORR)

    Baseline to measured stable disease

    Time frame: 2 years

  2. Disease-free survival(DFS) Baseline to measured date of recurrence or death from any cause

    Baseline to measured date of recurrence or death from any cause

    Time frame: 3 years

  3. bpCR

    After neoadjuvant chemotherapy and surgery, breast was free of any invasive cancer

    Time frame: immediately after surgery

  4. Adverse Events rate

    Evaluate the nature, incidence and severity of chemotherapy adverse events according to CTCAE 5.0

    Time frame: 1-year

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Dec 2026, 81 months after the start.

Of 43 non-industry phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 91. This study's planned 81 months is above that.

Counting every sponsor, half of 56 studies reached it within 57 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2020
First posted
Mar 2, 2020
StartActual
Mar 1, 2020
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 10, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04290793
Lead sponsor
Hebei Medical University Fourth Hospital
Responsible party
Liu Yunjiang (Director, Hebei Medical University Fourth Hospital) — Principal investigator
First posted
Mar 2, 2020
Start date
Mar 1, 2020
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
Jan 7, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pyrotinib · Epirubicin · Cyclophosphamide · Taxoids

Start the discussion